Although it has been possible to obtain a prescription for cannabis medicines in Switzerland for a number of years, it is not uncommon for patients to incur considerably higher costs than if they were to obtain cannabis products on the black market. Prof. Dr. med. Reto Auer, Bern Institute of Family Medicine, explained the nature of this dilemma in his presentation.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- AI in neurology
Control instead of a flood of data: AI makes big data and wearables usable
- Treatment of pancreatitis: current study data
How can the risk-benefit profile be improved?
- Prurigo and PN
Anti-inflammatory antipruritic therapy improves quality of life
- Pathophysiology, clinical significance and therapeutic consequences
Eosinophils in asthma
- Urothelial carcinoma
Perioperative innovations and organ-preserving strategies
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- GLA:D® program for back pain patients
Fewer consultations and reduction in the use of painkillers
- Nutrition for type 2 diabetes